The cyclin-dependent kinase inhibitor p21 is required for TGF-β1-induced podocyte apoptosis  by Wada, Takehiko et al.
Kidney International, Vol. 68 (2005), pp. 1618–1629
The cyclin-dependent kinase inhibitor p21 is required for
TGF-b1–induced podocyte apoptosis
TAKEHIKO WADA, JEFFREY W. PIPPIN, YOSHIO TERADA, and STUART J. SHANKLAND
Division of Nephrology, University of Washington, Seattle, Washington; and Homeostasis Medicine and Nephrology, Tokyo
Medical and Dental University, Tokyo, Japan
The cyclin-dependent kinase inhibitor p21 is required for TGF-
b1–induced podocyte apoptosis.
Background. Reduced podocyte number is a critical deter-
minant in the development of glomerulosclerosis. Transform-
ing growth factor-b1 (TGF-b1) induces podocyte apoptosis, but
the cell cycle events are not known. The cyclin-dependent ki-
nase (CDK) inhibitor p21 increases in podocytes in diseases
where TGF-b increases. Accordingly, we studied the role of
p21 in podocyte apoptosis.
Methods. Immortalized and primary p21+/+ and p21−/−
mouse podocytes were used. Apoptosis was measured by
Hoechst 33342 staining and caspase-3 activity following the
exposure to TGF-b1 or puromycin aminonucleoside. p21 and
specific Bcl-2–related family proteins levels were measured by
Western blot analysis. To prove a role for p21, we reconstituted
p21 expression in p21−/− podocytes utilizing an adenovirus
vector.
Results. TGF-b1 increased the protein levels of p21 in p21+/+
podocytes, and this coincided with apoptosis. In contrast,
TGF-b1 did not induce apoptosis in p21−/− podocytes. Restor-
ing p21 expression increased apoptosis in p21−/− podocytes
following exposure to TGF-b1. TGF-b1 increased the protein
levels of an antiapoptotic Bcl-2 in p21−/− podocytes, but not in
p21+/+ podocytes. Moreover, TGF-b1 did not increase Bcl-2
expression in p21−/− podocytes in which p21 expression was re-
stored. Finally, puromycin aminonucleoside also induced apop-
tosis in p21+/+ podocytes, but not in p21−/− podocytes.
Conclusion. Podocyte apoptosis induced by TGF-b1 and
puromycin aminonucleoside requires p21, and Bcl-2 plays a cru-
cial role downstream of p21 in mediating this effect. These re-
sults suggest that p21 may play a critical role in the decrease in
podocyte number in disease status accompanied by increased
TGF-b1.
Total glomerular cell number reflects a balance be-
tween an increase in cell number due to proliferation,
and a decrease in cell number due to programmed cell
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death, or apoptosis. Apoptosis occurs in many forms of
renal disease, and during development. The glomerular
visceral epithelial cell, also called the podocyte, is a highly
specialized and differentiated cell with a limited mitotic
capacity and, therefore, a limited ability to be replaced if
lost. There is a growing body of literature showing that
reduced podocyte number is a critical determinant under-
lying the development of glomerulosclerosis and there-
fore progressive renal failure in diabetic and nondiabetic
renal disease.
Recent studies have focused on elucidating the mech-
anisms of podocyte apoptosis. Schiffer et al [1] showed
increased podocyte apoptosis in transforming growth
factor-b (TGF-b) transgenic mice, which leads to a de-
crease in podocyte number and glomerulosclerosis. The
TGF-b superfamily consists of secreted peptides includ-
ing three TGF-b isoforms (TGF-b1, -b2, and -b3), ac-
tivins, and bone morphogenetic proteins (BMP). TGF-b
is a multifunctional cytokine that plays an important role
in glomerular diseases. In renal cells, TGF-b has effects on
extracellular matrix (ECM) protein production, prolifer-
ation, hypertrophy, and apoptosis. The molecular mech-
anisms involved are complex, and within the podocyte,
includes the activation of Smad proteins [2]. Smad7 am-
plifies the proapoptotic effect of TGF-b in podocytes
and p38 mitogen-activated protein (MAP) kinase and
caspase-3 are also involved in podocyte apoptosis induced
by TGF-b1 [1].
Studies have shown that TGF-b also mediates its ac-
tions through specific cell cycle regulatory proteins. Cell
proliferation regulated at the level of the cell cycle [3] re-
quires that cyclin-dependent kinases (CDK) be activated
by partner cyclins. Cyclin-CDK complexes are negatively
regulated by CDK inhibitors, which inhibit cell prolifera-
tion by causing cell cycle arrest. Two families of CDK in-
hibitors have been identified on the basis of sequence ho-
mology and their target cyclin-CDK complexes. The Ink4
family of CDK inhibitors, p15Ink4b p16Ink4a, and p18Ink4c,
specifically inhibit G1 phase-cyclin-CDK. The Cip/Kip
family of CDK inhibitors, which includes p21Cip1/Waf1
(p21), p27Kip1 (p27), and p57Kip2 (p57), share homology
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at the amino terminus and inhibit G1 and S phase cyclin-
CDK complexes. Although the traditional view was that
cell cycle proteins were only involved in proliferation, re-
cent studies by our group and others have shown a link
between the cell cycle and apoptosis. There is a grow-
ing body of evidence showing that certain cyclin-CDKs
[4, 5] and CDK inhibitors participate in apoptosis [6–10],
beyond their role in the regulation of proliferation.
We have shown that p21 is increased in podocytes in
experimental membranous nephropathy, coincident with
the increase in TGF-b levels [11]. TGF-b and p21 are also
increased in diabetic nephropathy, and p21 levels increase
upon exposure to TGF-b in culture. However, the exact
role of p21 in mediating the apoptotic effects of TGF-b
in podocytes are not known, Accordingly, in the current
study, we assessed the role of p21 in TGF-b1–induced
podocyte apoptosis.
METHODS
Cells in culture
Two types of cultured mouse podocytes were utilized
in these studies.
Temperature-sensitive immortalized mouse podocytes.
To study the role of p21 in TGF-b1–induced apoptosis,
immortalized podocytes were derived from p21+/+ and
p21−/− immortomice, produced by intercrossing trans-
genic H-2Kb-tsA58 mice (Immortomice) (The Jackson
Laboratory, Bar Harbor, ME, USA) [12] with p21+/+
mice and p21−/− mice, respectively. Podocytes were
identified and characterized as described below.
Experiments were performed utilizing early passage
(passages 10 to 18), growth-restricted, conditionally im-
mortalized mouse podocytes. Under these conditions,
podocytes are fully differentiated and quiescent, resem-
bling the in vivo phenotype. Cells were grown in RPMI
1640 media containing 10% fetal bovine serum (FBS)
(Summit Biotechnology, Ft. Collins, CO, USA), penicillin
(100 U/mL), streptomycin (100 lg/mL), sodium pyru-
vate (1 mmol/L) (all from Irvine Scientific, Santa Ana,
CA, USA), HEPES buffer (10 mmol/L) (Sigma Chem-
ical Co., St. Louis, MO, USA), and sodium bicarbonate
(0.075%) (Sigma Chemical Co.). In order to passage cells,
podocytes were grown under “growth permissive” condi-
tions (33◦C in the presence of interferon-gamma (IFN-c)
(50 U/mL) (Roche Diagnostics Co., Indianapolis, IN,
USA). In order for podocytes to acquire a differentiated
and quiescent phenotype, cells were grown under “re-
strictive conditions” at 37◦C in 95% air/5% CO2 without
IFN for longer than 11 days. We studied two different
clones for each cell type (i.e., −/− and +/+) in all exper-
iments.
Primary cultured mouse podocytes. In order to show
that a role for p21 was not limited to immortalized cells,
and was not influenced by the presence of the T anti-
gen, we also utilized primary cultured mouse podocytes.
Accordingly, primary cultured mouse podocytes were
derived from p21−/− and p21+/+ mice that were not
crossed with Immortomice, and these were character-
ized and established in culture as described previously
[13]. These cells are not temperature or interferon sen-
sitive. In brief, glomeruli were sieved as previously de-
scribed [14] and initially grown on vitrogen-coated cell
culture plates in media containing 5% FBS, penicillin
(100 U/mL), streptomycin (100 lg/mL), and glutamine
(2 mmol/L) (Irvine Scientific) at 37◦C in 95% air/5%
CO2. Podocytes were then transferred and subsequently
grown on collagen I coated plates in 2:1 mixtures of
Dulbecco’s modified Eagle’s medium (DMEM) (Invit-
rogen Co., Carlsbad, CA, USA) and Ham’s F-12 medium
(Irvine Scientific), containing 5% FBS, penicillin (100
U/mL), streptomycin (100 U/mL), HEPES buffer (10
mmol/L) (Sigma Chemical Co.), and sodium bicarbon-
ate (0.075%) (Sigma Chemical Co).
Immunostaining
Podocytes derived from p21+/+ and p21−/− Immor-
tomice, growing on tissue culture plates, were char-
acterized by immunostaining and reverse transcription-
polymerase chain reaction (RT-PCR). After 14 days of
culture under growth restrictive conditions, cells from
mice were fixed for 20 minutes in methanol at –20◦C. Fol-
lowing a wash in phosphate-buffered saline (PBS), the
cells were incubated overnight at 4◦C with the follow-
ing podocyte-related antibodies: (1) WT-1 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), (2) synaptopodin
(gift of Peter Mundel, Einstein Collage of Medicine,
Brox, NY, USA), (3) CD2-associated protein (CD2AP)
(gift of Andrey Shaw, Washington University, St. Louis,
MO, USA), and (4) nephrin (gift of Harry Holthofer,
University of Helsinki, Finland). The expression of p21
was also determined using p21 monoclonal antibody (BD
Biosciences, Palo Alto, CA, USA). A secondary biotiny-
lated horse antimouse antibody (Vector Laboratories,
Burlingame, CA, USA) or a goat antirabbit antibody
(Vector Laboratories) was used, followed by an Alexa
Fluor 594-conjugated streptavidin (Molecular Probes,
Eugene, OR, USA). Negative controls included omitting
the primary antibody or the primary antibody was substi-
tuted with an irrelevant antibody. For all immunostains,
fibroblasts, which should not express podocyte proteins,
were also used as a negative control.
RT-PCR
To further characterize p21+/+ and p21−/− immor-
talized podocytes, RT-PCR was performed to determine
the mRNA expression of podocyte-related molecules
and p21. Total RNA was isolated from the cells cul-
tured under growth restrictive conditions for 14 days
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using TRI REAGENT (Sigma Chemical Co.) accord-
ing to the manufacturer’s protocol. cDNA was synthe-
sized using the oligo (dT) protocol contained in the
SuperScript First-Strand Synthesis System for RT-PCR
(Invitrogen Co.). cDNA was amplified using primer
sets specific for the mouse genes as follows: WT-1
forward primer 5′-TACCCAGGCTGCAATAAGAG-3′,
reverse primer 5′-AAGCAGTTTGCACACTTTCC-3′;
synaptopodin forward primer 5′-ACCAGCCAGATAG-
AGCAAAG-3′, reverse primer5′-AGCTGCACTAG-
GTCCAGCAA-3′; CD2AP forward primer 5′-GAT-
GATGAGTTAACTATCCGAG-3′, reverse primer 5′-
GCTTCCTCCTGAGCGTTGTGAG-3′; nephrin for-
ward primer 5′-GTTCAGCTGGGAGAGACTGG-3′,
reverse primer 5′-CTGGATGTTGGTGTGGTCTG-
3′; and p21 forward primer 5′-AGAGGGAGCCTG-
AAGACTGT-3′, reverse primer 5′-TCAGACACC-
AGAGTGCAAGA-3′. Negative controls consisted of
omitting the reverse transcriptase, and substituting this
with water. For all RT-PCR reactions, fibroblasts, which
should not express podocyte-related proteins, were also
used as a negative control.
The PCR reactions were performed as follows: 94◦C
for 5 minutes, followed by 25 or 30 cycles of 94◦C for
30 seconds, 55 or 58◦C for 30 seconds, and 72◦C for 1
minute. PCR products were separated on 1.4% ethidium
bromide–stained agarose gels.
Experimental design
To determine the biologic significance of the CDK in-
hibitor p21 in podocyte apoptosis, p21+/+ and p21−/−
temperature-sensitive immortalized mouse podocytes
and primary cultured mouse podocytes were utilized. To
show a role for p21 in podocyte apoptosis, apoptosis was
induced by two methods.
TGF-b1. In order to induce apoptosis in temperature-
sensitive immortalized p21−/− and p21+/+ mouse
podocytes, cells grown under growth restrictive condi-
tions for more than 11 days were incubated with medium
containing 5% FBS in the presence or absence of 5 ng/mL
of human recombinant TGF-b1 (R&D Systems Inc., Min-
neapolis, MN, USA) for 72 hours. In order to induce
apoptosis with TGF-b1 in primary cultured p21−/− and
p21+/+ mouse podocytes, cells were grown in low serum
(0.1% FBS)–containing media for 24 hours to induce
growth arrest, thus resembling the in vivo phenotype. Our
pilot data showed that 0.1% serum did not induce apop-
tosis (data not shown). Cells were then exposed to human
recombinant TGF-b1 at the concentration of 5 ng/mL for
24 hours.
Puromycin aminonucleoside. To determine the role
of the CDK inhibitor p21 in podocyte apoptosis beyond
TGF-b1, we also tested the effect of puromycin aminonu-
cleoside on apoptosis in p21+/+and p21−/−podocytes in
a limited number of experiments. Temperature-sensitive
immortalized and primary cultured mouse podocytes
were exposed to puromycin aminonucleoside (30 lg/mL)
(Sigma Chemical Co.) for 48 hours.
Measuring apoptosis
First, apoptosis was measured by staining with Hoechst
33342 (Sigma Chemical Co.) as we previously described
[6]. Podocytes were plated at a density of 5 × 104 cells/cm2
for Hoechst staining, and at each time point Hoechst
33342 was added to the media for 5 minutes before quan-
titation at several time points. Apoptosis was defined as
the presence of nuclear condensation as we have previ-
ously reported. After Hoechst staining, the percentage of
the cells with nuclear condensation was calculated on at
least 300 cells. All experiments were performed a mini-
mum of three times.
Second, to determine the activity of caspase-3, we uti-
lized the BD ApoAlert Caspase Colorimetric Assay Kit
(BD Biosciences), according to the manufacturer’s in-
structions. This assay uses the spectrophotometric detec-
tion of the chromophore p-nitroaniline (pNA) after its
cleavage by caspase-3 from the labeled caspase-specific
substrates. Adherent cells together with floating cells in
the media were collected, and a cell lysate was obtained
using cell lysis buffer included in the kit. After the cell
lysate was incubated with caspase-3 substrate DEVD-
pNA (final concentration 50 lmol/L) at 37◦C for 1 hour,
the caspase-3 activities were measured by the absorbance
at 405 nm by a Packard Spectracount microplate reader.
Western blot analysis
Western blot analysis was performed to measure the
protein levels of specific cell cycle proteins and Bcl-2
family proteins in podocytes exposed to TGF-b1. Cells
were washed three times with ice-cold PBS and har-
vested by a trypsin digestion at 37◦C for 3 minutes. Cells
were pelleted by centrifugation (1200 rpm for 3 minutes
at 4◦C), washed twice with ice-cold PBS, and then sus-
pended in lysis buffer containing 1% Triton, 10% glyc-
erol, 20 mmol/L HEPES, 100 mmol/L NaCl, and protease
inhibitor cocktail (Roche Molecular Biochemicals, Indi-
anapolis, IN, USA). Following an overnight freeze-thaw
cycle, lysates were cleared by centrifugation at 14,000
rpm for 5 minutes at 4◦C and protein concentration was
determined by BCA Protein Assay Kit (Pierce, Rock-
ford, IL, USA) according to the manufacturer’s proto-
col. Reducing buffer was added to each protein extract
and samples boiled for 5 minutes. Reduced protein sam-
ples (5 to 10 lg per lane) were then loaded on an 8%
sodium dodecyl sulfate (SDS)-polyacrylamide gel and
subsequently transferred to a polyvinylidine difluoride
(PVDF) membrane (Immobilon-P) by electroblotting at
350 mA for 75 minutes. After blocking for 30 minutes
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in 5% nonfat dried milk, membranes were incubated
overnight (4◦C) with the following primary antibodies:
anti-p21 monoclonal antibody (BD Pharmingen, San
Diego, CA, USA), anti-Bax monoclonal antibody (Santa
Cruz Biotechnology), anti-Bcl-2 monoclonal antibody
(Santa Cruz Biotechnology), anti-Bcl-xL monoclonal an-
tibody (Santa Cruz Biotechnology), and antitubulin mon-
oclonal antibody (NeoMarkers, Fremont, CA, USA).
Following three wash cycles with Tris-buffered saline
containing 0.1% Tween (TBST), membranes were incu-
bated with antimouse alkaline phosphatase–conjugated
secondary antibody (Promega, Madison, WI, USA) for 1
hour at room temperature. The resultant bands were de-
tected with chromagen 5-bromo-4-chloro-3-inodyl phos-
phate/nitro blue tetrazolium (Sigma Chemical Co.). We
repeated each Western blot analysis using protein from
at least three different and separate experiments and
performed densitometric quantitation using NIH image
(version 1.63, the National Institutes of Health) in order
to perform statistical analysis.
Recombinant p21 adenovirus
In order to show a definitive role for p21 in apopto-
sis, recombinant adenoviral p21 [15] was used to restore
p21 levels in p21−/− podocytes. Replication-defective,
recombinant adenovirus AxCAp21 was constructed by
homologous recombination between the expression cos-
mid cassette and the parental virus genome. A modified
version of the methods described by Kanegae et al [16],
Miyake et al [17], and Chang et al [18] was used. Briefly,
the expression cosmid cassette was constructed by insert-
ing the expression unit, comprised of the CAG (chicken
b-actin promoter + cytomegalovirus enhancer) promoter
[17], p21 coding sequence, and polyA sequence, into the
SwaI site of Adex1w. Adex1w is a 42 kb cosmid contain-
ing 31 kb adenovirus type 5 genome lacking E1A, E1B,
and E3 genes. The expression cosmid cassette and aden-
ovirus DNA terminal protein complex (DNA-TPC) were
cotransfected into 293 cells by the calcium phosphate pre-
cipitation method. Adex1w and DNA-TPC were kindly
provided by Dr. I Saito (Laboratory of Molecular Ge-
netics, Institute of Medical Science, University of Tokyo,
Tokyo, Japan). The 293 cells, derived from human em-
bryonic kidney, were transformed by incorporating ade-
novirus E1A- and E1B-deleted replication-deficient ade-
novirus vectors. The full-length rat p21 cDNA (2.1 kb)
(kindly provided by Dr. A. Noda, Meiji Cell Technology,
Odawara, Japan) [19] was isolated by restriction enzyme
digested with BamHI, and blunted by using a DNA blunt-
ing kit (Takara, Tokyo, Japan). Then p21 cDNA was lig-
ated into the SmaI site of the expression cosmid cassette
with T4 DNA ligase. A recombinant adenovirus express-
ing LacZ gene (AxCALacZ) was provided by Dr. I. Saito
served as control [16]. Each adenovirus preparation was
titrated by 50% tissue culture infectious dose (TCID50)
method on 293 cells. Viral stocks were stored at −80◦C
and thawed on ice for 5 minutes before use.
Both primary cultured and temperature-sensitive
immortalized mouse podocytes were infected with
adenovirus. Temperature-sensitive immortalized mouse
podocytes were plated at a density of 5.0 × 103/cm2 and
grown under growth restrictive conditions for more than
10 days. Differentiated podocytes were incubated for 24
hours in the 10% FBS-containing RPMI medium. After
they were infected with adenovirus vectors at a titer of
5.1 × 105 pfu [multiplicity of infection (MOI = 51)] in 5%
FBS-containing culture medium for 24 hours, the medium
was replaced with medium containing human recombi-
nant TGF-b1 at the concentration of 5 ng/mL. Primary
cultured mouse podocytes were plated at a density of
5.0 × 103/cm2 and incubated for 24 hours in
DMEM/Ham’s F-12 medium containing 5% FBS.
Podocytes were infected with adenovirus vectors contain-
ing either LacZ gene (control) or p21 gene at the titer
of 1.674 × 106 pfu (MOI = 167.4) for 24 hours under
low serum conditions (0.1% FBS-containing medium).
Following a 24-hour incubation, the media was replaced
with media containing 5% FBS and human recombinant
TGF-b1 at a concentration of 5 ng/mL
The efficiency of transfection was determined by X-
galactosidase (X-gal) staining. Both primary cultured and
temperature-sensitive immortalized mouse podocytes
were infected with AxCALacZ at the titers described
above, and the cells were fixed with 10% buffered forma-
lin (Globe Scientific Inc., Paramus, NJ, USA) for 5 min-
utes at room temperature. The fixed cells were stained
in 2% X-gal reagent (0.1% Triton-X, 1 mmol/L MgCl2, 5
mmol/L K4 [Fe(CN)6], and 5 mmol/L K3 [Fe (CN)6]) at
37◦C overnight.
Statistical analysis
Statistical analysis was performed using Statview 4.5
software program (Abacus Concepts, Berkeley, CA,
USA). Statistical significance was evaluated using Stu-
dent t test or Mann-Whitney U test. A P value of less
than 0.05 was considered to be statistically significant.
RESULTS
Characterization of temperature-sensitive immortalized
p21+/+ and p21−/− podocytes
We have previously reported on the characterization of
the primary podocytes used in this study [13]. To analyze
the role of p21 in podocyte apoptosis under quiescent
conditions in vitro, we generated temperature-sensitive
immortalized p21+/+ and p21−/− mouse podocytes as
described above. As we had observed in the temperature-
sensitive mouse podocytes that we have previously re-
ported [20], these cells continued growing when cultured
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Fig. 1. Characterization of immortalized p21+/+ and p21−/− mouse podocytes. (A) Immunostaining was performed on fixed cells for podocyte
specific proteins in p21+/+ and p21−/− podocytes, and in fibroblasts, used as a negative control. Staining for WT-1 are positive in nuclei in p21+/+
and p21−/− podocytes, but not in fibroblasts. Synaptopodin (Synpo), CD2-associated protein (CD2AP), and nephrin are present in the cytoplasm
and at the cell periphery in p21+/+ and p21−/− podocytes, but not in fibroblasts. p21 staining was detected in the nuclei in p21+/+ podocytes
grown under restrictive conditions, but not in p21−/− podocytes. (B) Reverse transcription-polymerase chain reaction (RT-PCR). The mRNA
transcripts for WT-1, CD2AP, and nephrin were detected in p21+/+ and p21−/− podocytes, but not in fibroblasts. Positive bands for synaptopodin
were detected in all cells. Transcripts for p21 were detected in p21+/+ podocytes, but not in p21−/− podocytes. Reactions with total RNA isolated
from the cells were performed in the presence (+RT) or absence (−RT) of reverse transcriptase.
at 33◦C in the media containing 50 U/mL of IFN-c. Af-
ter thermoswitching to 37◦C and withdrawal of IFN-c, the
cells underwent arrest of proliferation and the cell bodies
enlarged with the formation of processes.
To characterize immortalized p21+/+ and p21−/−
mouse podocytes we examined the expression of
podocyte-related proteins at the protein and mRNA
level. As shown in Figure 1, p21+/+ and −/− cells showed
positive staining for the immunohistologic markers for
podocytes under growth restrictive conditions including
WT-1, synaptopodin, CD2AP, and nephrin. We also ob-
served the absence of immunostaining for markers of fi-
broblasts, mesangial cells (a-smooth muscle actin stain-
ing) and endothelial cells (factor VIII staining) (data not
shown).
In addition to measuring the protein levels, we also
measured mRNA expression of these markers by RT-
PCR. As shown in Figure 1B, transcripts of the podocyte-
related molecules WT-1, CD2AP, and nephrin were
detected in both p21+/+ and p21−/− immortalized
mouse podocytes, but not in fibroblasts. Synaptopodin
mRNA was detected however in all three cell types. We
also confirmed that p21 mRNA was not expressed in
p21−/− podocytes, as one might expect. These results
confirmed that the p21+/+ and p21−/− cells we gener-
ated for this study were indeed podocytes.
TGF-b1 increases p21 protein levels
In the present study, we first performed Western blot
analysis using protein cell lysate from cells incubated with
TGF-b1 to see the effect of TGF-b1 on the expression of
p21 in podocytes. Western blot analysis and densitomet-
ric quantitation (using tubulin as a housekeeping protein)
showed that incubation of temperature-sensitive immor-
talized p21+/+ podocytes with TGF-b1 (5 ng/mL) for
72 hours caused a 2.24-fold increase in p21 protein lev-
els (Fig. 2). Primary cultured mouse podocytes incubated
with TGF-b1 also showed a 2.61-fold increase of p21 ex-
pression (data now shown). These results demonstrated
that incubation of cultured podocytes with TGF-b1 in-
creased the protein level of CDK inhibitor p21 in vitro,
and provided a rationale to test the hypothesis that p21
mediated the apoptotic effects of TGF-b1.
TGF-b1–induced apoptosis requires p21
Since the expression levels of p21 were higher in
podocytes exposed to TGF-b1 than in control cells ex-
posed to vehicle, we tested the hypothesis that p21 has
a role in TGF-b1–induced apoptosis. To test this possi-
bility, apoptosis was induced in two different clones of
temperature-sensitive immortalized p21+/+ and p21−/−
mouse podocytes grown under restrictive conditions for
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Fig. 2. Transforming growth factor-b1 (TGF-b1) increased p21 expression in cultured mouse podocytes. (A) Western blot analysis showed that
TGF-b1 (5 ng/mL) increased the protein levels for p21 in temperature-sensitive p21+/+ mouse podocytes at 24, 48, and 72 hours. Tubulin was
used as control for protein loading. (B) The expression levels were determined using densitometric analysis. The protein levels of p21 increased in
response to TGF-b1 in a time-dependent manner, and the p21 level in the cells exposed to TGF-b1 was 2.24-fold higher than control at 72 hours.
11 days, and then exposed to TGF-b1 for 72 hours. The
percentage of apoptotic cells was determined by care-
ful observation of the morphology of nuclei stained with
Hoechst 33342. The number of p21+/+ mouse podocytes
with characteristic morphologic features of apoptosis [21]
increased 2.80-fold and 4.87-fold in response to TGF-
b1 at 48 hours (P < 0.005 vs. control) and 72 hours (P
< 0.005 vs. control), respectively. In contrast, p21−/−
mouse podocytes did not undergo apoptosis at 24, 48, and
72 hours of incubation with TGF-b1. Thus, as shown in
Figure 3A and B, immortalized p21+/+ podocytes under-
went significantly more apoptosis than p21−/− podocytes
(P < 0.005 at 48 hours and 72 hours, respectively).
We confirmed these data using two different clones of
temperature-sensitive p21−/− mouse podocytes
We also performed similar experiments in p21−/− and
p21+/+ primary cultured podocytes that were not im-
mortalized. Figure 3C shows that p21+/+ primary cul-
tured mouse podocytes underwent significant apoptosis
at 12 hours and 24 hours in response to TGF-b1 (P < 0.05
vs. control). In contrast, TGF-b did not induce apopto-
sis in primary p21−/− podocytes at 12 or 24 hours. To
insure that the difference in TGF-b1 responsiveness was
not due to TGF-b receptor levels, we measured the pro-
tein levels of TGF-b type II receptor. Our data showed
no difference in the expression levels of TGF-b type II
receptors between in p21+/+ and in p21−/− podocytes
(data not shown), suggesting that the lack of TGF-b1–
induced apoptosis in immortalized and primary p21−/−
podocytes was not due to TGF-b1 responsiveness.
Caspase-3 is an active cell-death protease involved
in the execution phase of apoptosis, and it has been
shown that podocyte apoptosis induced by TGF-b is
caspase-3–dependent [1]. To determine if TGF-b1 acti-
vates caspase pathway and to confirm the Hoechst stain-
ing data shown earlier, we measured caspase-3 activities
in p21+/+ and p21−/− immortalized podocytes exposed
to TGF-b1. As shown in Figure 4, the exposure to TGF-
b1 for 72 hours caused a significant increase of caspase-
3 activity by 1.6-fold in p21+/+ podocytes (P < 0.0001
vs. control). In contrast, there was no significant acti-
vation of caspase-3 in p21−/− podocytes exposed to
TGF-b1.
Taken together, these results suggest that p21 is re-
quired for TGF-b1–induced podocyte apoptosis in vitro
in both immortalized and primary podocyte cell lines.
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Fig. 3. Transforming growth factor-b1
(TGF-b1) induced apoptosis in p21+/+
podocytes, but not in p21−/− podocytes. (A)
Temperature-sensitive immortalized p21+/+
and −/− mouse podocytes were exposed
to TGF-b1 (5 ng/mL) and apoptosis was
measured by Hoechst staining. Apoptosis
was detected in p21+/+ podocytes (arrows),
whereas p21−/− podocytes did not undergo
apoptosis. (B) Quantitation of apoptosis
showed that TGF-b1 induced apoptosis in
temperature-sensitive p21+/+ podocytes
in a time-dependent manner. In contrast,
TGF-b1 did not induce apoptosis in p21−/−
podocytes. (C) TGF-b1 induced apoptosis in
primary cultured p21+/+ mouse podocytes in
a time-dependent manner. p21−/− podocytes
exposed to TGF-b1 underwent significantly
less apoptosis in response to TGF-b1.
Restoring p21 levels rescues p21−/− podocytes from
apoptosis
To prove the hypothesis that TGF-b1–induced
podocyte apoptosis requires p21, we investigated TGF-
b1–induced apoptosis in temperature-sensitive immor-
talized p21−/− podocytes in which p21 expression was
restored using a p21 adenovial vectors. We used Ax-
CALacZ as a control vector. Cells infected with Ax-
CALacZ showed greater than 90% efficiency in gene
transfer as measured by X-gal staining (Fig. 5A). We
also checked the expression of p21 in AxCAp21-
infected p21−/− podocytes by Western blot analysis,
and our results confirm that p21 levels were restored
in p21−/− podocytes following transfection (Fig. 5B).
Following transfection with control (AxCALacZ) and
p21 (AxCAp21) adenoviral vectors for 24 hours, p21−/−
podocytes were then exposed to TGF-b1 and the num-
ber of apoptotic nuclei measured 24 hours later. As
shown in Figure 5C, apoptosis was significantly increased
in p21−/− podocytes transfected with AxCAp21 in re-
sponse to TGF-b1 compared to cells infected with Ax-
CAp21 and exposed to vehicle (9.57% vs. 2.21%) (P <
0.005). In contrast, p21−/− podocytes infected with con-
trol AxCALacZ did not undergo apoptosis in the pres-
ence of TGF-b1 (Fig. 5C).
To confirm that p21 is required for podocyte apoptosis,
primary cultured p21−/− podocytes were also infected
with AxCALacZ or AxCAp21. Similar to the immortal-
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Fig. 4. Transforming growth factor-b1 (TGF-b1) activates caspase-3 in
p21+/+, but not p21−/− podocytes. Incubation of p21+/+ podocytes
with TGF-b1 (5 ng/mL, for 72 hours) increased caspase-3 activity by
59.8% compared to control. In contrast, caspase-3 was not activated in
p21−/− podocytes in response to TGF-b1.
ized cells, the restoration of p21 expression in primary
p21−/− podocytes also caused increased apoptosis in re-
sponse to TGF-b1 (data not shown). These results sup-
port the notion that p21 is required in TGF-b1–induced
apoptosis in podocytes.
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Fig. 5. Restoration of p21 in p21−/− podocytes made them susceptible to transforming growth factor-b1 (TGF-b1)–induced apoptosis. (A) X-
galactosidase (X-gal) staining showed that more than 90% of p21−/− podocytes were transfected with AxCALacZ. (B) The Western blot analysis
showed that p21 was successfully restored in p21−/− podocytes infected with p21 vector AxCAp21 at 24 hours after infection. Tubulin was used
as control for protein loading. (C) TGF-b1 (5 ng/mL) induced apoptosis in temperature-sensitive immortalized p21−/− podocytes infected with
AxCAp21 (9.26 ± 2.46%) (P < 0.005 vs. control), while it did not cause any significant increase in apoptosis in control AxCALacZ-infected p21−/−
podocytes.
Differential expression of Bcl-2 family-related proteins is
p21 dependent
To explore potential mediators of TGF-b1–induced
podocyte apoptosis, we next examined the expression of
Bcl-2 related family proteins by Western blot analysis,
as a candidate mechanism. Bcl-2 and Bcl-xL are anti-
apoptotic, whereas Bax is proapoptotic. We compared
the change of the protein levels in response to TGF-b1
between p21+/+ and p21−/− podocytes, and in p21−/−
podocytes infected with AxCAp21 and AxCALacZ. The
results are shown in Figures 6 and 7.
Bcl-2. The first finding was that in p21+/+ podocytes,
Bcl-2 protein was detected under basal conditions, and
that TGF-b1 had no effect on its expression (Fig. 6A).
The second observation was that Bcl-2 protein levels were
substantially reduced (80.8%) in p21−/−podocytes in the
absence of TGF-b1 compared to p21+/+ (Fig. 6A). The
third observation was that incubation with TGF-b1 in-
creased the levels of Bcl-2 (182%) (P < 0.001 vs. p21+/+)
in p21−/− podocytes (Fig. 6A). To test the effect of p21
on Bcl-2 levels, p21−/− cells were infected with control
AxCALacZ and p21 AxCAp21 vectors, and Bcl-2 expres-
sion was measured, and the results are shown in Figure 7.
Restoring p21 levels in p21−/− podocytes substantially
increased Bcl-2 levels (56.0%) suggesting that p21 may
regulate Bcl-2 expression. Finally, the effect of TGF-b1
on Bcl-2 was determined in p21−/− podocytes before
and after restoring p21 levels. Figure 6 shows that TGF-
b1 increased Bcl-2 levels in p21−/− podocytes that were
not transfected. Moreover, Figure 7 shows that TGF-b1
increased Bcl-2 levels in p21−/− podocytes transfected
with control AxCALacZ (60.6% increase) but not in the
podocytes transfected with p21 AxCAp21 (3.71% de-
crease).
Bcl-xL. Figure 6 shows that in the absence of TGF-
b1, the protein levels of Bcl-xL were similar in p21+/+
and p21−/− podocytes. Figure 6 also shows that TGF-b1
had no effect on the levels of the antiapoptotic Bcl-xL
protein in p21+/+ or p21−/− podocytes. To determine if
p21 levels also regulate Bcl-xL, p21−/− podocytes were
transfected with control AxCALacZ and p21 AxCAp21
vectors, and the results are shown in Figure 7. Restor-
ing p21 levels in p21−/− podocytes reduced Bcl-xL levels
(23.5% reduction) while the levels were slightly increased
(13.6%) in the podocytes transfected with control Ax-
CALacZ followed by exposure to the same growth factor.
However, these changes did not reach statistical signifi-
cance. These results suggest that in the presence of p21,
TGF-b1 reduces Bcl-xL levels, and that this may favor or
underlie increased apoptosis.
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Fig. 6. The expressions of Bcl-2 family pro-
teins in p21+/+ and −/− podocytes exposed
to transforming growth factor-b1 (TGF-b1).
(A) Western blot analysis in p21+/+ and −/−
podocytes exposed to TGF-b1 (5 ng/mL) for
24 hours. Tubulin was used as control for
protein loading. (B) The expression levels
were determined using densitometric analy-
sis. Western blot analysis of Bcl-2 family pro-
teins demonstrated that the protein levels of
Bcl-2 showed a 167.6% increase in p21−/−
podocytes exposed to TGF-b1 (5 ng/mL),
while TGF-b1 increased Bcl-2 by only 3.79%
in p21+/+ podocytes. There was no significant
difference in the levels for Bcl-xL and Bax in
p21+/+ and p21−/− podocytes.
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podocytes suppressed the up-regulation of
Bcl-2 by exposure to transforming growth
factor-b1 (TGF-b1). (A) Western blot anal-
ysis in temperature-sensitive immortalized
p21−/− mouse podocytes infected with
AxCALacZ or AxCAp21. Tubulin was
used as control for protein loading. (B) The
expression levels of Bcl-2–related family pro-
teins were determined using densitometric
analysis. Western blot analysis showed that
the protein levels of Bcl-2 were up-regulated
in response to TGF-b1 (5 ng/mL) in p21−/−
podocytes infected with AxCALacZ (60.6%
increase). In contrast, TGF-b1 decreased
Bcl-2 by 3.71% in the p21-restored p21−/−
podocytes. Bcl-xL protein levels were
down-regulated in AxCAp21-infected
p21−/− podocytes (23.5%) while slightly
up-regulated in AxCALacZ-infected p21−/−
podocytes (13.6%), however, the difference
was not statistically significant.
Bax. The expression of Bax was similar in p21+/+
and p21−/− podocytes in the absence of TGF-b1 (Fig. 6).
Although TGF-b1 reduced Bax levels by 15.8% and by
41.6% in p21+/+ and p21−/− podocytes, respectively,
this difference was not statistically significant. Figure 7
shows that restoring p21 levels had no effect on Bax lev-
els. Taken together, the decrease in the levels of Bax in
response to TGF-b1 is p21 independent.
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Fig. 8. p21−/− podocytes are resistant to puromycin aminonucleo-
side–induced apoptosis. Puromycin aminonucleoside (30 lg/mL) in-
duced apoptosis in temperature-sensitive immortalized p21+/+ mouse
podocytes. p21−/− podocytes underwent significantly less apoptosis
when exposed to the same concentration of puromycin aminonucle-
oside.
p21 is also required for puromycin aminonucleoside–
induced podocyte apoptosis
Puromycin aminonucleoside has been widely used as
an animal model for minimal change disease and focal
segmental glomerulosclerosis. Recently, it has been de-
scribed that podocytes undergo apoptosis in response to
puromycin aminonucleoside in vivo [22, 23] and in vitro
[24]. To determine if the role of p21 in the podocyte
apoptosis was specific to TGF-b1 and if p21 also plays a
role in apoptosis caused by another stimulus, we exposed
p21+/+ and p21−/− podocytes to puromycin aminonu-
cleoside (30 lg/mL) for 48 hours and counted the number
of nuclei which showed features of apoptosis. As shown in
Figure 8, puromycin aminonucleoside induced apoptosis
in p21+/+ podocytes. In contrast, puromycin aminonu-
cleoside barely induced apoptosis in p21−/− podocytes
(Fig. 8). We obtained similar results using two different
clones of temperature-sensitive immortalized p21+/+
and p21−/− podocytes under growth restrictive condi-
tions and also in primary cultured p21−/− and p21+/+
mouse podocytes (data not shown). These results suggest
that p21 is also required in puromycin aminonucleoside–
induced podocyte apoptosis, and that the proapoptotic
function of p21 is not limited exclusively to TGF-b1–
induced apoptosis.
DISCUSSION
The reduction in podocyte number is closely associ-
ated with the development of glomerulosclerosis in ex-
perimental and human glomerular disease. Kriz, Gretz,
and Lemley [25] proposed that podocyte depletion and/or
detachment and the inability of podocytes to replicate
causes the initial lesions of focal segmental glomeru-
losclerosis and eventual glomerular tuft destruction. This
pathway has been verified in diabetic [26, 27] and nondia-
betic human glomerular diseases [28]. Although podocyte
apoptosis has been shown to reduce podocyte number,
the mechanisms underlying podocyte apoptosis, and the
implications of cell cycle regulatory proteins and Bcl-
2 family proteins in the process, remain to be under-
stood. In the present study we show that p21 is re-
quired for apoptosis in podocytes induced by TGF-b1
and puromycin aminonucleoside, and that Bcl-2 and per-
haps Bcl-xL are downstream of p21.
TGF-b is a pleiotropic cytokine, with numerous cell
and tissue activities. Studies have shown that TGF-b in-
duces apoptosis in many cell types [29–35]. In the kidney,
it has been demonstrated that TGF-b induces apoptosis
in mesangial cells [36, 37], glomerular endothelial cells
[38, 39], and more recently, in podocytes[1, 40]. Schiffer et
al [1] has shown that podocytes undergo apoptosis at early
stages in the course of progressive glomerulosclerosis in
TGF-b1 transgenic mice, and that TGF-b1 and Smad7 in-
duce apoptosis cooperatively through separate pathways.
They have also reported recently that CD2AP functions
as a mediator for repression of apoptosis signaling by
TGF-b in podocytes, and that CD2AP is required for acti-
vation of phosphatidylinositol 3-kinase (PI3K)/AKT and
extracellular signal-regulated kinase (ERK)1/2 by TGF-
b [40].
We focused on the role of the CDK inhibitor p21 in
TGF-b–induced apoptosis, because studies have clearly
shown that both TGF-b and p21 are increased in
podocytes in certain diseases. In the current study, we
show that TGF-b1 increases p21 levels in cultured
podocytes, similar to what has been previously reported in
nonrenal cells [41–43]. Similar to recently reported stud-
ies, our results showed that TGF-b1 induced apoptosis in
p21+/+ podocytes, as did puromycin aminonucleoside.
However, a major finding in this study was that TGF-b1
and puromycin aminonucleoside did not induce apoptosis
in immortalized and primary cultured p21−/− podocytes.
Similar to the results obtained by Hoechst staining, al-
though TGF-b1 increases caspase-3 activity in p21+/+
podocytes, TGF-b1 did not activate caspase-3 in p21−/−
podocytes. Taken together, these findings support our ob-
servations on TGF-b1–induced apoptosis in p21+/+ and
p21−/− podocytes. This was not due to differences in
TGF-b1 receptor levels. Furthermore, when p21 levels
were restored in p21−/− podocytes by adenoviral trans-
fection, TGF-b1 induced apoptosis in p21−/− podocytes
to a level similar to p21+/+ podocytes. The role of p21
may be cell-type and injury-specific, in that it is proapop-
totic in certain cells, and antiapoptotic in others. Taken
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together, the results of the current study support the no-
tion that p21 is required for TGF-b1 induced apoptosis
in podocytes. One might therefore speculate that an in-
crease in p21 in podocytes is an attempt to suppress any
increase in cell number, and that this effect is due to both
a reduction in podocyte proliferation as we have previ-
ously reported [13, 44], and an increase in apoptosis as
we now show.
We next examined potential mechanisms whereby p21
is required for podocyte apoptosis, and focused on Bcl-
2–related family proteins. The first findings were that lev-
els of the anti-apoptotic Bcl-2 proteins were significantly
lower in p21−/− podocytes at baseline and restoring p21
levels by adenoviral tranfection “normalized” Bcl-2 lev-
els. This suggests that Bcl-2 is downstream of p21 and
that p21 expression is necessary for normal Bcl-2 ex-
pression. The second finding was that Bcl-2 levels were
markedly up-regulated in p21−/− podocytes in response
to TGF-b1 while Bcl-2 levels were not altered by TGF-
b1 in p21+/+ podocytes. Moreover, restoring p21 levels
in p21−/− cells by transfection significantly prevented
the increase in Bcl-2 expression in response to TGF-b1.
This suggests that the up-regulation of antiapoptotic Bcl-
2 is suppressed in the presence of p21 under “disease
conditions.” Finally, we did not show any statistically sig-
nificant changes in the expression of Bcl-xL and Bax in
response to TGF-b1 in p21+/+, p21−/−, or p21-restored
p21−/− podocytes. Schiffer et al [1] demonstrated that
Bax expression is increased by TGF-b1 and it peaked at
6 hours, a time point earlier than we studied in the cur-
rent manuscript. Taken together, these findings suggest
that Bax may initiate TGF-b1–induced apoptosis at early
time points and antiapoptotic Bcl-2 and Bcl-xL cannot
suppress the apoptosis at later time points in the pres-
ence of p21.
Although previous studies have shown that podocytes
undergo apoptosis under various disease conditions in
vivo, the small number of apoptotic podocytes detected
in those studies makes it difficult to investigate podocyte
apoptosis in vivo. Our group recently demonstrated that
viable podocytes are shed into the urine in the passive
Heymann nephritis model of membranous nephropathy,
and the streptozotocin diabetic model [45, 46]. We specu-
late that podocytes that have undergone apoptosis in situ
are also shed into the urine.
CONCLUSION
Our data suggest that the CDK-inhibitor p21 is re-
quired and essential for podocyte apoptosis induced by
TGF-b1. The mechanisms of this effect are not com-
pletely defined, but suggest that p21 is upstream of the
anti-apoptotic proteins Bcl-2 and perhaps Bcl-xL. These
results show that in addition to its antiproliferative ef-
fect, p21 also regulates podocyte number by increasing
apoptosis.
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